Article from Medscape (July 28)
Clinical trial data showing that two biosimilar rituximab products are comparable to the reference product, Rituxan (Genentech) (in Europe, MabThera), were published online July 13 in the Lancet Haematology.
"The results of these two trials will certainly promote the introduction of rituximab biosimilar into daily, clinical practice in the immediate future," write editorialists in an accompanying commentary.
Clinical trial data showing that two biosimilar rituximab products are comparable to the reference product, Rituxan (Genentech) (in Europe, MabThera), were published online July 13 in the Lancet Haematology.
"The results of these two trials will certainly promote the introduction of rituximab biosimilar into daily, clinical practice in the immediate future," write editorialists in an accompanying commentary.